Target intelligence / Profile preview

Streptococcus pneumoniae capsular polysaccharide serotype 6B (CPS6B) (CPS6B)

Target
CPS6B
Molecular classification
Bacterial capsular polysaccharide, Antigen
01

Overview

Streptococcus pneumoniae capsular polysaccharide serotype 6B (CPS6B) is a complex carbohydrate polymer that constitutes the outermost protective layer of the bacterium. It functions as a primary virulence factor by shielding the pathogen from the host's immune system, specifically by preventing opsonophagocytosis by white blood cells (NIH, 2023). Serotype 6B is a member of Serogroup 6, which includes structurally similar serotypes 6A, 6C, and 6D; these variants differ primarily in the specific linkages between their sugar subunits, such as rhamnose and ribitol (Journal of Clinical Microbiology, 2007). In clinical practice, this polysaccharide is a key component of pneumococcal conjugate and polysaccharide vaccines, where it acts as an antigen to stimulate the production of protective antibodies (CDC, 2022). While antibodies generated against 6B can provide cross-reactivity with 6A, 6C, and 6D, modern multivalent vaccines often include both 6A and 6B to ensure broader coverage across the serogroup (Clinical and Vaccine Immunology, 2011). Immunization targeting this molecule is essential for preventing invasive pneumococcal diseases, including pneumonia, meningitis, and febrile bacteremia, particularly in high-risk populations like children and the elderly (WHO, 2019). The polysaccharide is often conjugated to a carrier protein, such as CRM197, to convert the T-cell independent response into a T-cell dependent one, enhancing memory and efficacy in infants (StatPearls, 2023).

Other names
Pneumococcal polysaccharide serotype 6BPn6B CPSSerogroup 6 capsular polysaccharideStreptococcus pneumoniae serotype 6AStreptococcus pneumoniae serotype 6CStreptococcus pneumoniae serotype 6D
02

Mechanism of action

Induction of active immunity through the production of serotype-specific opsonophagocytic antibodies that facilitate bacterial clearance (CDC, 2022).

03

Biological functions

Immune evasionVirulence factorInhibition of opsonophagocytosis
04

Disease associations

InfectionPneumoniaMeningitisBacteremiaOtitis media
05

Safety considerations

Serotype replacementHypersensitivity reactionsInjection site reactionsReduced immunogenicity in immunocompromised individuals
06

Interacting drugs

Pneumococcal 13-valent conjugate vaccine (PCV13)

3 more in the full profile.

07

Biomarkers

Opsonophagocytic activity (OPA) titerSerotype-specific IgG concentration

Beyond the preview

Go deeper on Streptococcus pneumoniae capsular polysaccharide serotype 6B (CPS6B) (CPS6B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptococcus pneumoniae capsular polysaccharide serotype 6B (CPS6B) (CPS6B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call